Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoHTTP: Fulvestrant and Chemoimmunotherapy in HER2+/ER+ Breast Cancer
NCT02345772Phase 2Terminated
- Sponsor
- Western Regional Medical Center
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fulvestrant in breast cancer, sponsored by Western Regional Medical Center. Primary endpoint: Pathological Complete Remission Rate at 1 year. Started Jul 2014; status: terminated.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02345772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345772.